Brokers Offer Predictions for GSK’s Q1 Earnings (NYSE:GSK)

GSK PLC Sponsored ADR (NYSE:GSK) – Research analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for shares of GSK in a report issued on Tuesday, September 2nd. Zacks Research analyst Team now expects that the pharmaceutical company will earn $1.15 per share for the quarter, up from their previous forecast of $1.11. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q1 2027 earnings at $1.18 EPS and Q2 2027 earnings at $1.22 EPS.

A number of other equities research analysts have also issued reports on the company. Wall Street Zen upgraded GSK from a “hold” rating to a “buy” rating in a research note on Sunday, August 3rd. Berenberg Bank reiterated a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. Six investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $37.38.

GSK Trading Up 0.5%

NYSE:GSK opened at $39.55 on Thursday. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm has a market capitalization of $80.56 billion, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 1.71 and a beta of 0.53. GSK has a one year low of $31.72 and a one year high of $44.19. The business has a fifty day moving average price of $38.48 and a 200-day moving average price of $38.31.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.GSK’s revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Twin Peaks Wealth Advisors LLC purchased a new position in shares of GSK during the second quarter valued at about $25,000. HHM Wealth Advisors LLC grew its position in shares of GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC purchased a new position in shares of GSK during the first quarter valued at about $31,000. Richardson Financial Services Inc. grew its position in shares of GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock valued at $33,000 after purchasing an additional 472 shares in the last quarter. Finally, SOA Wealth Advisors LLC. lifted its holdings in shares of GSK by 252.1% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 605 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be given a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.3%. GSK’s dividend payout ratio (DPR) is presently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.